Wall Street Can Now Bet on Whether New Drugs Succeed. Doctors Are Warning About the Consequences.
Healthcare Investigations | Medical Research & Ethics
A clinical trial is designed to answer whether a new treatment works. Now, outside traders can take financial positions on whether some of those experiments will succeed. Physicians and researchers are asking whether that creates a dangerous conflict—or a valuable new source of information.
Imagine a patient participating in a clinical trial for an experimental Alzheimer’s treatment. The patient is hoping for better care. The researchers are working to obtain reliable evidence. Meanwhile, someone who has never met the patient can buy a contract that pays off if the trial meets its specified goal.
That is no longer merely a thought experiment. On July 16, 2026, prediction-market exchange Kalshi announced a pilot with biopharmaceutical intelligence company AppliedXL featuring event contracts linked to selected late-stage clinical trial results and US Food and Drug Administration (FDA) decisions.
In October, medical researchers began sounding a public alarm. Commentaries in The New England Journal of Medicine and JAMA warned that putting direct financial stakes on unfinished research could create pressures not adequately addressed by existing safeguards.
The distinction that matters: The existence of these markets is documented. The possibility that their incentives could threaten research integrity is a serious, published concern. The sources reviewed for this article do not establish that a clinical trial has already been manipulated, that a participant has been harmed, or that an FDA decision has been corrupted because of these contracts.
What Are People Actually Betting On?
Unlike buying shares in a pharmaceutical company—which reflects the entire business—an event contract can focus on one yes-or-no question. Did a named Phase 3 study meet its registered primary endpoint? Did the FDA approve a particular drug by a specified deadline? What was the outcome of an FDA advisory committee vote?
According to Kalshi and AppliedXL, the pilot uses predefined resolution rules tied to public records, including ClinicalTrials.gov, FDA approval letters, and advisory committee voting records. AppliedXL compiles evidence, while Kalshi retains final responsibility for settling its contracts under its exchange rules.
Examples announced in July included an Alzheimer’s clinical trial involving AR1001 and a regulatory decision concerning an investigational multiple myeloma therapy. These were examples of questions available to trade on—not claims about the therapies’ efficacy or their ultimate outcomes.
At the beginning of the pilot, the companies said clinical trial markets would be limited to late-stage studies that had completed enrollment. That detail is central to the controversy.
Why Medical Researchers Are Alarmed
A September 2026 editorial in Science argued that enrollment closure is not the same as completion of a clinical trial. Once enrollment stops, patients may still be undergoing follow-up, researchers may still be collecting endpoint measurements, and confidential results may not yet be public.
An October 29 JAMA Viewpoint, authored by Jay B. Lusk, Robert M. Califf, Ann Marie Navar, and Emily C. O’Brien, questioned whether market safeguards can adequately protect against threats to recruitment, retention, measurement, and evidence generation.
The basic worry is straightforward: a financial market tied directly to a trial result may give some participants an incentive to seek confidential information—or potentially influence the process producing the result.
That does not mean every trader is acting improperly or that the trials in question have been compromised. It means clinical research now presents a new category of conflict-of-interest questions.
If somebody can profit from a trial failing, what safeguards make sure the experiment remains untouched?
Three Potential Conflicts That Physicians Should Understand
Researchers, employees, contractors, or others may learn important facts before results are released. A direct event contract creates a specific financial interest in those facts.
Trials continue after recruitment closes. Endpoint measurement, participant follow-up, and data management require protection from outside incentives.
Patients consent to research for medical and scientific purposes. Seeing outsiders wager on results could complicate trust even without any proven wrongdoing.
A trading prohibition is meaningful only to the extent it can be monitored and enforced. Clinical trials involve many individuals and organizations.
What Safeguards Have the Companies Announced?
Kalshi said it would require employment verification and prohibit trading by people holding material nonpublic information. The firms also described safeguards including listing trial contracts only after enrollment is complete, excluding studies exclusively enrolling children, and using public evidence to resolve the contracts.
These measures deserve consideration, not dismissal. Closing enrollment before listing may reduce a visible market’s potential influence on who joins a study. Predetermined rules could also reduce disputes over what counts as success.
Critics respond that neither safeguard ends the issue. Clinical studies can remain active after enrollment. Material nonpublic information may exist well before public disclosure. Whether exclusions and trading restrictions can be effectively enforced is an important unresolved question.
Is There an Argument in Favor of These Markets?
Yes. Supporters contend that prediction markets can combine dispersed information into a public probability. Drug development is uncertain, and estimates of success are often produced privately by investors, research organizations, and pharmaceutical companies.
A publicly visible market could, in principle, offer a continuously updated signal about how participants interpret available evidence. It may also create an alternative to forecasts that are difficult to compare or audit.
But a market price is not clinical evidence. It does not establish that a drug is safe, effective, appropriate for a particular patient, or likely to receive approval. Trading prices can also be influenced by thin liquidity, speculation, incomplete information, and the design of individual contracts.
The strongest defense of the concept is informational value. The strongest objection is whether that value justifies adding financial stakes before an experiment is finished.
Why a Failed Trial Can Still Be Valuable Medicine
When a well-designed study fails to meet its primary endpoint, the result can be scientifically useful. It can help researchers avoid ineffective approaches, refine hypotheses, understand safety signals, or redirect resources toward better options.
That scientific value is separate from the financial outcome of a prediction contract. A trader who profits when a trial fails has won a financial position, not necessarily contributed to better medicine.
Physicians should preserve that distinction in public discussion. A negative trial result is not evidence of incompetence or wrongdoing. Likewise, a positive result does not alone prove that a treatment is safe and effective for broad clinical use.
Where Is the Line Between Forecasting and Gambling on Patients?
Different people may draw the line differently. Some would allow contracts tied to FDA decisions but prohibit positions in unfinished clinical experiments. Others would permit carefully regulated markets while strengthening insider-information rules, monitoring suspicious activity, and creating independent oversight.
Authors writing in Science took a stronger position, urging a ban on wagers tied to ongoing clinical trial outcomes before those results become public. A September analysis in JAMA Health Forum discussed both risks and oversight approaches rather than treating every form of prediction market as identical.
These are policy arguments, not settled proof that any one regulatory approach will work best.
Five Questions Medical Professionals Should Ask
- Who can see unpublished results? Map which investigators, employees, contractors, and partners have access to material nonpublic clinical or regulatory information.
- What conflict-of-interest policies apply? Review trial-site, sponsor, institutional review board, employment, and research-integrity rules regarding outside financial positions.
- How is ongoing research protected? Preserve independence in enrollment, follow-up, measurement, data handling, and adverse-event reporting.
- What should patients be told? Discuss with research ethics and legal professionals whether new external market activity warrants additional communication or policy review.
- How would a suspected problem be escalated? Ensure staff know the appropriate institutional compliance, research integrity, and regulatory reporting channels.
Could This Create New Professional Liability Exposures?
Potentially, but not automatically. The existence of a clinical-trial prediction market does not itself produce a malpractice claim or create insurance coverage.
For research-intensive medical organizations, new questions may arise around conflicts of interest, clinical-trial governance, cyber and data protection, professional responsibility, and contractual obligations. Any resulting exposures would depend on the facts, applicable law, individual policies, and the conduct involved.
Medical malpractice, research-related liability, cyber insurance, directors and officers coverage, and other policies address different types of risk. They should not be treated as interchangeable. Research organizations considering operational changes should have qualified counsel and insurance professionals evaluate actual contracts, policies, and practices.
Read more about medical malpractice insurance and professional liability considerations at Island Insurance Group.
The Bottom Line: Medical Research Is Not a Sporting Event
Clinical trials carry uncertainty. That uncertainty is necessary: honest medical research exists precisely because scientists do not yet know the answer.
Prediction markets promise a new way to express those uncertainties as public probabilities. Yet they also introduce financial incentives aimed at specific outcomes of unfinished medical research.
The debate is not resolved by declaring these markets either innovative or corrupt. It requires evidence about their benefits, credible oversight of potential conflicts, and an uncompromising commitment to research integrity.
Patients enroll in clinical trials so medicine can discover what works. The public deserves confidence that the answer is determined by science—not by a market’s financial interests.
Protecting a Medical Practice Means Understanding Emerging Risks
Island Insurance Group helps physicians and healthcare businesses evaluate professional liability and commercial insurance as their services and operational exposures evolve. A coverage review is not a substitute for research ethics or legal advice, but it can help identify insurance questions that deserve attention.
Schedule a 30-Minute ConsultationExplore more healthcare, insurance, and business guidance in the Island Insurance Group Resources Center.
Research and Sources
- Kalshi, Biotech Prediction Markets Pilot, July 16, 2026.
- AppliedXL, Biopharma Prediction Markets FAQ, August 2026.
- Lusk et al., Wagering on Unfinished Experiments—Prediction Markets and Clinical Trial Integrity, JAMA, October 29, 2026.
- Vogel, Yaeger, and Wouters, Clinical Trial Prediction Markets—Information, at What Cost?, NEJM, October 2026.
- Yang and Kesselheim, Ban Bets on Unfinished Clinical Trials, Science, September 2026.
- Kanter, Prediction Markets in Clinical Trials and Drug Approval, JAMA Health Forum, September 25, 2026.
This article is for educational and editorial purposes only and is not medical, legal, investment, trading, or insurance coverage advice. It does not recommend participation in prediction markets. Individual coverage is subject to the actual terms, conditions, exclusions, and underwriting of the policy. Information is current to November 5, 2026.
